Australian biotech and vaccine manufacturer CSL has finalised all regulatory clearances for its $17.2 billion all cash takeover of a complementary healthcare business, Swiss pharmaceutical manufacturer Vifor. Completion of the acquisition, announced in December will now take place by 9 August. CSL CEO Paul Perreault said the Vifor business would add near-term value to the company and a path to sustainable growth. The massive takeover expands CSL's global footprint into complementary areas including haematology, thrombosis, cardiovascular and transport treatments, as well as delivering a high quality R&D development pipeline.